Abstract:
The present invention relates to a method for diagnosing cancer using information on the aberrant glycosylation of a glycoprotein involved in cancer progress. More particularly, the present invention relates to a cancer diagnosis peptide marker which is screened by the steps of: separating a glycoprotein aberrantly glycosylated according to the occurrence and progress of cancer from the blood of a lung cancer patient by using lectin; and selecting a marker peptide produced by the hydrolysis of the glycoprotein isolated by lectin. The marker peptide can be effectively used as a cancer diagnosis marker and for the diagnosis of cancer.
Abstract:
The preset invention relates to a high resolution mass spectrometry based novel bioinformatics platform for the identification of glycation proteins and advanced glycation end-product. Particularly, the bioinformatics platform of the present invention facilitates an efficient and accurate investigation of quantitative changes of glycation proteins and advanced glycation end-products which are included in various types of samples but had not been informed yet, and uses a high resolution mass spectrometry, and thereby can be effectively used for the prediction or diagnosis of a disease including cancer by examining a disease marker in a sample.
Abstract:
The preset invention relates to a high resolution mass spectrometry based novel bioinformatics platform for the identification of glycation proteins and advanced glycation end-product. Particularly, the bioinformatics platform of the present invention facilitates an efficient and accurate investigation of quantitative changes of glycation proteins and advanced glycation end-products which are included in various types of samples but had not been informed yet, and uses a high resolution mass spectrometry, and thereby can be effectively used for the prediction or diagnosis of a disease including cancer by examining a disease marker in a sample.